The cancer caregiving burden trajectory over time: varying experiences of perceived versus objectively measured burden
CONCLUSIONS: Cancer caregiving is dynamic; CGs must adjust to the progression of the patient's disease. We found an association between subjective and objective burden both within and between CGs. Black CGs were more likely to report lower subjective burden compared to their White counterparts. More detailed investigation of the sociocultural components that affect caregiver experience of burden is needed to better understand how and where to best intervene with targeted supportive care services.PMID:38652165 | DOI:10.1093/oncolo/oyae069 (Source: The Oncologist)
Source: The Oncologist - April 23, 2024 Category: Cancer & Oncology Authors: Laura A Siminoff Maureen Wilson-Genderson Marcin Chwistek Maria Thomson Source Type: research
A phase IV study to evaluate the safety of fruquintinib in Chinese patients in real-world clinical practice
CONCLUSIONS: The safety profile of fruquintinib in the real world was generally consistent with that in clinical studies, and the incidence of TEAEs was numerically lower than known VEGF/VEGFR inhibitor-related AEs. Fruquintinib exhibited manageable safety and tolerability in Chinese patients in the real-world setting.PMID:38642091 | DOI:10.1093/oncolo/oyae073 (Source: The Oncologist)
Source: The Oncologist - April 20, 2024 Category: Cancer & Oncology Authors: Jin Li Zhiqiang Wang Haijun Zhong Yifu He Chen Zhang Zuoxing Niu Shujun Yang Tao Zhang Liangjun Zhu Yongqian Shu Yong Gao Jianjun Peng Yan Song Jian Li Ying Yuan Haibo Zhang Gengsheng Yu Yunqi Hua Jianjun Xiao Jianfei Fu Yulong Zheng Hua Xue Xian Luo Ming Source Type: research
Delays in presentation, diagnosis, and treatment in Sudanese women with breast cancer: a cross-sectional study
CONCLUSION: Most Sudanese women with breast cancer experience significant patient delays, often presenting at advanced stages. Factors like being single, older, and living in rural areas contribute to these delays. Increasing breast cancer education, improving healthcare access and addressing sociodemographic barriers can potentially expedite diagnosis and improve outcomes.PMID:38642908 | DOI:10.1093/oncolo/oyae066 (Source: The Oncologist)
Source: The Oncologist - April 20, 2024 Category: Cancer & Oncology Authors: Esraa S A Alfadul Badria Tebaig Salma S Alrawa Ammar Tarig Elgadi Ensaf E M A Margani Maab E B Adam Mawaheb Sh Adem Mohamoud Safa A M Elhassan Moawia Mohammed Ali Elhassan Source Type: research
A Prognostic Survival Model Incorporating Patient-Reported Outcomes for Transplant-Ineligible Patients With Multiple Myeloma
Oncologist. 2024 Apr 18:oyae041. doi: 10.1093/oncolo/oyae041. Online ahead of print.ABSTRACTDeveloping prognostic tools specifically for patients themselves represents an important step in empowering patients to engage in shared decision-making. Incorporating patient-reported outcomes may improve the accuracy of these prognostic tools. We conducted a retrospective population-based study of transplant-ineligible (TIE) patients with multiple myeloma (MM) diagnosed between January 2007 and December 2018. A multivariable Cox regression model was developed to predict the risk of death within 1-year period from the index date. W...
Source: The Oncologist - April 18, 2024 Category: Cancer & Oncology Authors: Hira Mian Hsien Seow Amaris K Balitsky Matthew C Cheung Anastasia Gayowsky Jason Tay Tanya M Wildes Arleigh McCurdy Alissa Visram Irwindeep Sandhu Rinku Sutradhar Source Type: research
Evolving assessment pathways for precision oncology medicines to improve patient access: a tumor-agnostic lens
CONCLUSIONS: Our call to action is to expand access to comprehensive genomic testing, foster a learning health care system, enable fast and equitable access to cost-effective treatments, and ultimately improve health outcomes.PMID:38630538 | DOI:10.1093/oncolo/oyae060 (Source: The Oncologist)
Source: The Oncologist - April 17, 2024 Category: Cancer & Oncology Authors: Priscila Radu Gayathri Kumar Amanda Cole Aikaterini Fameli Mark Guthrie Lieven Annemans Jan Geissler Antoine Italiano Brian O'Rourke Entela Xoxi Lotte Steuten Source Type: research
Impact of smoking status on clinical outcomes in patients with metastatic renal cell carcinoma treated with first-line immune checkpoint inhibitor-based regimens
CONCLUSION: Smoking status does not appear to independently influence the clinical outcomes to first-line ICI-based regimens in patients with mRCC. Nonetheless, patient counseling on tobacco cessation remains a crucial aspect of managing patients with mRCC, as it significantly reduces all-cause mortality.PMID:38630540 | DOI:10.1093/oncolo/oyae072 (Source: The Oncologist)
Source: The Oncologist - April 17, 2024 Category: Cancer & Oncology Authors: Eddy Saad Georges Gebrael Karl Semaan Marc Eid Ren ée Maria Saliby Chris Labaki Nicolas Sayegh J Connor Wells Kosuke Takemura Matthew Scott Ernst Audreylie Lemelin Naveen S Basappa Lori A Wood Thomas Powles D Scott Ernst Aly-Khan A Lalani Neeraj Agarwal Source Type: research
Human malignancies associated with persistent HPV infection
Oncologist. 2024 Apr 17:oyae071. doi: 10.1093/oncolo/oyae071. Online ahead of print.ABSTRACTHuman papillomavirus (HPV)-associated malignancies account for ~5% of human cancers worldwide. Thirteen, or more, HPV types are oncogenic, but infection with these viruses is common and usually cleared within 2 years. Only infections that become persistent are associated with the development of cancer, often occurring several decades later. These cancers mostly arise in 6 different anatomical regions: 5 are anogenital (anus, cervix, penis, vagina, and vulva) and the sixth is the oropharynx. Oncogenic HPVs promote cellular proliferat...
Source: The Oncologist - April 17, 2024 Category: Cancer & Oncology Authors: Alison A McBride Source Type: research
Evolving assessment pathways for precision oncology medicines to improve patient access: a tumor-agnostic lens
CONCLUSIONS: Our call to action is to expand access to comprehensive genomic testing, foster a learning health care system, enable fast and equitable access to cost-effective treatments, and ultimately improve health outcomes.PMID:38630538 | DOI:10.1093/oncolo/oyae060 (Source: The Oncologist)
Source: The Oncologist - April 17, 2024 Category: Cancer & Oncology Authors: Priscila Radu Gayathri Kumar Amanda Cole Aikaterini Fameli Mark Guthrie Lieven Annemans Jan Geissler Antoine Italiano Brian O'Rourke Entela Xoxi Lotte Steuten Source Type: research
Impact of smoking status on clinical outcomes in patients with metastatic renal cell carcinoma treated with first-line immune checkpoint inhibitor-based regimens
CONCLUSION: Smoking status does not appear to independently influence the clinical outcomes to first-line ICI-based regimens in patients with mRCC. Nonetheless, patient counseling on tobacco cessation remains a crucial aspect of managing patients with mRCC, as it significantly reduces all-cause mortality.PMID:38630540 | DOI:10.1093/oncolo/oyae072 (Source: The Oncologist)
Source: The Oncologist - April 17, 2024 Category: Cancer & Oncology Authors: Eddy Saad Georges Gebrael Karl Semaan Marc Eid Ren ée Maria Saliby Chris Labaki Nicolas Sayegh J Connor Wells Kosuke Takemura Matthew Scott Ernst Audreylie Lemelin Naveen S Basappa Lori A Wood Thomas Powles D Scott Ernst Aly-Khan A Lalani Neeraj Agarwal Source Type: research
Human malignancies associated with persistent HPV infection
Oncologist. 2024 Apr 17:oyae071. doi: 10.1093/oncolo/oyae071. Online ahead of print.ABSTRACTHuman papillomavirus (HPV)-associated malignancies account for ~5% of human cancers worldwide. Thirteen, or more, HPV types are oncogenic, but infection with these viruses is common and usually cleared within 2 years. Only infections that become persistent are associated with the development of cancer, often occurring several decades later. These cancers mostly arise in 6 different anatomical regions: 5 are anogenital (anus, cervix, penis, vagina, and vulva) and the sixth is the oropharynx. Oncogenic HPVs promote cellular proliferat...
Source: The Oncologist - April 17, 2024 Category: Cancer & Oncology Authors: Alison A McBride Source Type: research
Comorbidity profiling identifies potential subtype of elderly patients with nasopharyngeal carcinoma
CONCLUSION: Our study shed light on the potential comorbidity patterns in elderly patients with NPC, thereby providing valuable insights into the development of comprehensive health management strategies for this specific population.PMID:38625619 | DOI:10.1093/oncolo/oyae063 (Source: The Oncologist)
Source: The Oncologist - April 16, 2024 Category: Cancer & Oncology Authors: Ying Li Yuhui Pan Zongwei Huang Lishui Wu Wenxi Wu Siqi Xu Zihan Chen Xin Chen Jun Lu Sufang Qiu Source Type: research
Comorbidity profiling identifies potential subtype of elderly patients with nasopharyngeal carcinoma
CONCLUSION: Our study shed light on the potential comorbidity patterns in elderly patients with NPC, thereby providing valuable insights into the development of comprehensive health management strategies for this specific population.PMID:38625619 | DOI:10.1093/oncolo/oyae063 (Source: The Oncologist)
Source: The Oncologist - April 16, 2024 Category: Cancer & Oncology Authors: Ying Li Yuhui Pan Zongwei Huang Lishui Wu Wenxi Wu Siqi Xu Zihan Chen Xin Chen Jun Lu Sufang Qiu Source Type: research
A process to reanalyze clinical DNA sequencing data for biomarker matching in the Lung-MAP Master Protocol
Oncologist. 2024 Apr 10:oyae062. doi: 10.1093/oncolo/oyae062. Online ahead of print.ABSTRACTFor cancer clinical trials that require central confirmation of tumor genomic profiling, exhaustion of tissue from standard-of-care testing may prevent enrollment. For Lung-MAP, a master protocol that requires results from a defined centralized clinical trial assay to assign patients to a therapeutic substudy, we developed a process to repurpose existing commercial vendor raw genomic data for eligibility: genomic data reanalysis (GDR). Molecular results for substudy assignment were successfully generated for 369 of the first 374 pat...
Source: The Oncologist - April 10, 2024 Category: Cancer & Oncology Authors: Joel W Neal Katherine Minichiello Ryan Brennick Richard S P Huang Matthew C Hiemenz Cornel Amler Jyoti Patel Roy Herbst Karen L Reckamp Hossein Borghaei Louise Highleyman Mary W Redman Lincoln W Pasquina David E Kozono Source Type: research
A process to reanalyze clinical DNA sequencing data for biomarker matching in the Lung-MAP Master Protocol
Oncologist. 2024 Apr 10:oyae062. doi: 10.1093/oncolo/oyae062. Online ahead of print.ABSTRACTFor cancer clinical trials that require central confirmation of tumor genomic profiling, exhaustion of tissue from standard-of-care testing may prevent enrollment. For Lung-MAP, a master protocol that requires results from a defined centralized clinical trial assay to assign patients to a therapeutic substudy, we developed a process to repurpose existing commercial vendor raw genomic data for eligibility: genomic data reanalysis (GDR). Molecular results for substudy assignment were successfully generated for 369 of the first 374 pat...
Source: The Oncologist - April 10, 2024 Category: Cancer & Oncology Authors: Joel W Neal Katherine Minichiello Ryan Brennick Richard S P Huang Matthew C Hiemenz Cornel Amler Jyoti Patel Roy Herbst Karen L Reckamp Hossein Borghaei Louise Highleyman Mary W Redman Lincoln W Pasquina David E Kozono Source Type: research
A process to reanalyze clinical DNA sequencing data for biomarker matching in the Lung-MAP Master Protocol
Oncologist. 2024 Apr 10:oyae062. doi: 10.1093/oncolo/oyae062. Online ahead of print.ABSTRACTFor cancer clinical trials that require central confirmation of tumor genomic profiling, exhaustion of tissue from standard-of-care testing may prevent enrollment. For Lung-MAP, a master protocol that requires results from a defined centralized clinical trial assay to assign patients to a therapeutic substudy, we developed a process to repurpose existing commercial vendor raw genomic data for eligibility: genomic data reanalysis (GDR). Molecular results for substudy assignment were successfully generated for 369 of the first 374 pat...
Source: The Oncologist - April 10, 2024 Category: Cancer & Oncology Authors: Joel W Neal Katherine Minichiello Ryan Brennick Richard S P Huang Matthew C Hiemenz Cornel Amler Jyoti Patel Roy Herbst Karen L Reckamp Hossein Borghaei Louise Highleyman Mary W Redman Lincoln W Pasquina David E Kozono Source Type: research
